Related references
Note: Only part of the references are listed.A Meta-Analysis of the Prevalence of Cardiac Valvulopathy in Patients With Hyperprolactinemia Treated With Cabergoline
Craig E. Stiles et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new
Philippe Chanson et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis
Miao Yun Xia et al.
ENDOCRINE (2018)
Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
Sema Ciftci Dogansen et al.
PITUITARY (2016)
Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis
Jintao Hu et al.
PITUITARY (2015)
Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline
Shlomo Melmed et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
TREATMENT OF MACROPROLACTINOMAS WITH A NEW NON-ERGOT, LONG-ACTING DOPAMINERGIC DRUG, CV 205-502
JOHANNA W. VERLAAT et al.
CLINICAL ENDOCRINOLOGY (2010)
Recurrence of Hyperprolactinemia after Withdrawal of Dopamine Agonists: Systematic Review and Meta-Analysis
Olaf M. Dekkers et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Prolactinomas
Anne Klibanski
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Medical therapy of pituitary adenomas: Effects on tumor shrinkage
Annamaria Colao et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2009)
Cabergolina en la hiperprolactinemia y enfermedad valvular cardíaca
Marcos Lahera Vargas et al.
Endocrinologia y Nutricion (2009)
Prolactinom-Behandlung mit einem neuen Dopaminagonisten
T. Svoboda et al.
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT (2008)
Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: A meta-analysis from clinical studies
F. Bogazzi et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2008)
The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas
A Di Sarno et al.
CLINICAL ENDOCRINOLOGY (2000)
A randomized cross-over study comparing cabergoline and quinagolide in the treatment of hyperprolactinemic patients
DA de Luis et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2000)
Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas:: predictive value of pituitary scintigraphy with 123I-methoxybenzamide
A Colao et al.
CLINICAL ENDOCRINOLOGY (2000)
Share Paper
